世界の遺伝子検査市場展望2018:次世代シーケンス(NGS)、新型出生前診断(NIPT)、全ゲノムシーケンス(WGS)

◆英語タイトル:Genetic Testing Market Outlook 2018
◆商品コード:RNCOS410165
◆発行会社(リサーチ会社):RNCOS
◆発行日:2014年10月
◆ページ数:120
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:バイオ技術
◆販売価格オプション(消費税別)
Single user(1名使用)USD1,400 ⇒換算¥156,800見積依頼/購入/質問フォーム
Multi-userUSD2,200 ⇒換算¥246,400見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はRNCOS社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。RNCOS社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

A recent report, “Genetic Testing Market Outlook 2018”, provides an in-depth analysis of the current and future genetic testing market. A comprehensive introduction of gene-based tests, their working principles and types are covered in this report. On account of our analysis of the past and present market trends; drivers; and existing strengths and challenges; forecast for genetic testing has been drawn, according to which, the market is likely to grow at a CAGR of around 9% during 2013-2018.

Our report is an outcome of extensive interaction with industry experts which has led us to portray the updated status of genetic testing in various therapeutic areas, major geographies and significant industry applications. The genetic testing industry has seen several new product launches, active research innovations, strategic activities, launch of new DTC tests, and wider therapeutic applications.

The report effectively illustrates the role of genetic testing in diseases such as Cancer, Cystic Fibrosis, and Alzheimer. It also incorporates the information on disease prevalence, available tests, and genes that cause a particular disease. An extensive research and reliable statistics in terms of market size, developments and future performance for emerging sectors namely, Next-Generation Sequencing, Whole Genome Sequencing, Non Invasive Prenatal Diagnostics, and Personalized Medicine have been covered in the report.

Genetic testing is growing in both developing and developed nations with both industry and research personnel highlighting the significance of molecular biology. The report provides comprehensive analytics of key developments for major markets including the U.S., Europe and Asian countries, and their market overview. Country level analysis depicts the level of penetration for genetic testing, types of tests available, consumer perspectives, regulatory stringency and future growth.

The report also profiles the ten most active genetic testing market players worldwide: Abbott Laboratories, Roche Diagnostics, Myriad Genetics, Life Technologies, Agilent, Hologic, Illumina, Qiagen, Cepheid, and Affymetrix.

【レポートの目次】

1. Analyst View
2. Research Methodology
3. Genetic Testing Overview
3.1 Application and Advantages
3.2 Methods
4. Global Genetic Testing Market Overview
4.1 Market Outlook
4.2 Genetic Testing Laboratories – Unmet Need Analysis
4.3 Direct-to-Consumer (DTC) Genetic Testing
5. Disease-Wise Analysis
5.1 Alzheimer’s Disease
5.2 Cystic Fibrosis
5.3 Cancer
6. Country-Level Analysis
6.1 US
6.1.1 Market Overview
6.1.2 Recent Developments
6.2 Europe
6.2.1 Market Overview
6.2.2 Recent Developments
6.3 Asia
6.3.1 Market Overview
6.3.2 Recent Developments
7. Emerging Sectors
7.1 Next-Generation Sequencing (NGS)
7.2 Non-Invasive Prenatal Testing (NIPT)
7.3 Whole Genome Sequencing (WGS) for Cancer
7.4 Personalized Medicine
8. Genetic Testing Regulation
9. Competitive Assessment
9.1 Abbott Laboratories
9.1.1 Company Overview
9.1.2 Product Offering
9.1.3 Key Financials
9.1.4 Recent Developments
9.1.5 Strengths & Weaknesses
9.2 Roche Diagnostics
9.2.1 Company Overview
9.2.2 Product Offering
9.2.3 Key Financials
9.2.4 Recent Developments
9.2.5 Strengths & Weaknesses
9.3 Myriad Genetics, Inc.
9.3.1 Company Overview
9.3.2 Product Offering
9.3.3 Key Financials
9.3.4 Recent Developments
9.3.5 Strengths & Weaknesses
9.4 Life Technologies Corporation (Thermo Fisher Scientific)
9.4.1 Company Overview
9.4.2 Product Offering
9.4.3 Key Financials
9.4.4 Recent Developments
9.4.5 Strengths & Weaknesses
9.5 Agilent Technologies Inc.
9.5.1 Company Overview
9.5.2 Product Offering
9.5.3 Key Financials
9.5.4 Recent Development
9.5.5 Strengths & Weaknesses
9.6 Hologic, Inc.
9.6.1 Company Overview
9.6.2 Product Offering
9.6.3 Key Financials
9.6.4 Recent Developments
9.6.5 Strengths & Weaknesses
9.7 Illumina, Inc.
9.7.1 Company Overview
9.7.2 Product Offering
9.7.3 Key Financials
9.7.4 Recent Developments
9.7.5 Strengths & Weaknesses
9.8 Qiagen NV
9.8.1 Company Overview
9.8.2 Products Offering
9.8.3 Key Financials
9.8.4 Recent developments
9.8.5 Strengths and Weaknesses
9.9 Cepheid
9.9.1 Company Overview
9.9.2 Product Offering
9.9.3 Key Financials
9.9.4 Recent developments
9.9.5 Strengths and Weakness
9.10 Affymetrix, Inc.
9.10.1 Company Overview
9.10.2 Product Offering
9.10.3 Key Financials
9.10.4 Recent Developments
9.10.5 Strength and Weakness

List of Figures:

Figure 4-1: Genetic Testing Market (Billion US$), 2013-2018
Figure 4-2: Genetic Testing Market by Geography (%), 2013
Figure 4-3: Number of Companies in Biochemical DTC Genetic Testing Segment (2007-2010)
Figure 4-4: Number of DTC Genetic Testing Companies by Country
Figure 6-1: Number of Disorder, Genes, Labs, & Clinics for Genetic Testing (2013 & 2014)
Figure 6-2: Number of Genetic Tests (2013 & 2014)
Figure 6-3: US – Number of Genetic Tests Available in the Market (2008 & 2012)
Figure 6-4: US – Genetic Testing Equipment Market (Billion US$), 2013-2018
Figure 6-5: Europe – Genetic Testing Equipment Market (Billion US$), 2013-2018
Figure 7-1: Global – Next Generation Sequencing Market (Billion US$), 2013-2018
Figure 7-2: Global – NGS Application by Sector (%)
Figure 7-3: Global – Next Generation Sequencing Market by Player (%), 2012
Figure 7-4: US – Non-Invasive Prenatal Testing Market (Million US$), 2013-2018
Figure 7-5: US – Tapped and Untapped Personalized Cancer WGS Market (%), 2013
Figure 7-6: US – Personalized Cancer WGS Market (Million US$), 2013-2018
Figure 7-7: Organizational Transformation to Support Personalized Medicine
Figure 8-1: Genetic Testing Regulatory Agencies
Figure 9-1: Abbott Laboratories – Revenue Breakup by Geography (%), 2013
Figure 9-2: Abbott Laboratories – Revenue Breakup by Diagnostics Division (%), 2013
Figure 9-3: Roche Holding – Diagnostic Division Revenue by Geography (%), 2013
Figure 9-4: Roche Holding – Revenue Breakup by Business Division (%), 2013
Figure 9-5: Myriad Genetics – Revenue Breakup by Business Segment (%), 2013
Figure 9-6: Life Technologies – Revenue Breakup by Geography (%), 2012
Figure 9-7: Life Technologies – Revenue Breakup by Business Segment (%), 2012
Figure 9-8: Agilent – Revenue Breakup by Business Segment (%), 2013
Figure 9-9: Hologic – Revenue Breakup by Business Segment (%), 2013
Figure 9-10: Hologic – Revenue Breakup by Geography (%), 2013
Figure 9-11: Illumina – Revenue Breakup by Geography (%), 2013
Figure 9-12: Qiagen NV – Revenue Break up by Business Segment (%), 2013
Figure 9-13: Qiagen NV – Revenue Break up by Geography (%), 2013
Figure 9-14: Cepheid – Revenue Break up by Business Segment (%), 2013
Figure 9-15: Cepheid – Revenue Break up by Geography (%), 2013
Figure 9-16: Affymetrix – Revenue Breakup by Geography (%), 2013
Figure 9-17: Affymetrix – Revenue Breakup by Business Segment (%), 2013

List of Tables:

Table 4-1: Key DTC Genetic Testing Companies by Category
Table 4-2: Key Test Areas Offered in DTC Genetic Testing Segment
Table 7-1: FDA Approved Pharmacogenomic Biomarkers for Oncology
Table 9-1: Abbott Laboratories – Key Gene Based Products
Table 9-2: Abbott Laboratories – Financial Performance (Million US$), 2010-2012
Table 9-3: Roche Molecular Diagnostics – Key Gene Based Products
Table 9-4: Roche Holding – Financial Performance (Million CHF), 2011-2013
Table 9-5: Myriad Genetics – Key Gene Based Products
Table 9-6: Myriad Genetics – Financial Performance (Million US$), 2011-2013
Table 9-7: Life Technologies – Key Gene Based Products
Table 9-8: Life Technologies – Financial Performance (Million US$), 2010-2012
Table 9-9: Agilent – Key Gene Based Products
Table 9-10: Agilent – Financial Performance (Million US$), 2011-2013
Table 9-11: Hologic – Key Gene Based Products
Table 9-12: Hologic – Financial Performance (Million US$), 2011-2013
Table 9-13: Illumina – Key Gene Based Products
Table 9-14: Illumina – Financial Performance (Million US$), 2011-2013
Table 9-15: Qiagen NV – Key Gene Based Products
Table 9-16: Qiagen NV – Financial Performance (Million US$), 2011-2013
Table 9-17: Cepherid – Key Gene Based Products
Table 9-18: Cepheid – Financial Performance (Million US$), 2011-2013
Table 9-19: Affymetrix – Key Gene Based Products
Table 9-20: Affymetrix – Financial Performance (Million US$), 2011-2013



【レポートのキーワード】

遺伝子検査、次世代シーケンス(NGS)、新型出生前診断(NIPT)、全ゲノムシーケンス(WGS)

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[世界の遺伝子検査市場展望2018:次世代シーケンス(NGS)、新型出生前診断(NIPT)、全ゲノムシーケンス(WGS)]についてメールでお問い合わせはこちら


◆H&Iグローバルリサーチのお客様(例)◆